Aims: This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P-glycoprotein (P-gp) inhibitor itraconazole on the pharmacokinetics of the investigational neural precursor cell expressed, developmentally downregulated 8 (NEDD8)-activating enzyme inhibitor pevonedistat in patients with advanced solid tumours. Results: The ratios of geometric mean area under the concentration-time curves (n; 90% confidence interval) of pevonedistat in the presence vs. absence of fluconazole or itraconazole were 1.11 (12; 1.03-1.19) and 1.14 (33; 1.07-1.23), respectively.
The ubiquitin-proteasome system plays an important role in cell survival, proliferation and apoptosis by regulating protein homeostasis through ubiquitination. 1 Proteins are targeted for degradation by the proteasome through the addition of a polyubiquitin chain by E3 ubiquitin ligases, of which the largest sub-family are the cullin-Really Interesting New Gene (RING) ligases (CRLs). 2 CRLs are activated via the binding of the small ubiquitin-like protein NEDD8 (neural precursor cell expressed, developmentally downregulated 8), which is facilitated by NEDD8-activating enzyme (NAE). As several substrates for CRLs are linked to cancer pathogenesis, including p27, cMYC, p-IκBα, hypoxia-inducible factor-1 (HIF1), and mammalian target of rapamycin (mTOR), CRLs are attractive targets for the development of antitumour agents. 2, 3 Pevonedistat (TAK-924/MLN4924) is a first-in-class, investigational, small molecule inhibitor of NAE. Pevonedistat inhibits the activity of NAE by forming a pevonedistat-NEDD8 adduct, which remains tightly bound to active NAE, preventing it from processing NEDD8 for CRL conjugation and resulting in CRL substrate accumulation and apoptotic cell death. 4, 5 Pevonedistat has demonstrated antitumour activity in preclinical studies of solid tumour, lymphoma, and acute myelogenous leukaemia (AML) xenograft mouse models, as well as single-agent activity in patients with advanced solid tumours and haematologic malignancies. or intermittent days, with little or no notable drug accumulation. 10, 12, 13 This is consistent with a mean terminal elimination half-life (t 1/2 ) of approximately 10-11 h estimated across doses and schedules. 6 Preclinical studies demonstrated that hepatic metabolism appeared to be the major route of elimination for pevonedistat, with metabolisation predominantly by cytochrome P450 (CYP) 3A4 (data on file). The contribution of CYP3A4 to pevonedistat biotransformation was estimated to be 97%, which was above the 25% threshold of potential clinical relevance for drug-drug interactions (DDIs) according to the guidelines set by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). 14, 15 These in vitro metabolism studies suggested that CYP3A4 inhibition could lead to a clinically meaningful increase in pevonedistat exposure. Additionally, pevonedistat was a substrate of the transporter multidrug resistance protein 1 (MDR1)/P-glycoprotein (P-gp) in vitro (data on file).
Based on these results, we conducted a study to assess the potential DDI of pevonedistat with the moderate CYP3A inhibitor fluconazole and the strong CYP3A and P-gp inhibitor itraconazole in patients with solid tumours to inform strategies for managing potential DDIs with moderate and strong CYP3A inhibitors in future clinical studies of pevonedistat and, ultimately, support adequate labelling.
2 | METHODS
| Study design
This was an open-label, multicentre, parallel-group, two-arm, phase I clinical pharmacology study in adult patients with advanced solid tumours. The study was composed of two parts ( Figure 1 ): a 24-day part that examined potential DDI of pevonedistat with CYP3A inhibitors (Part A), followed by an (optional) extension where participating patients received (after a washout period of at least 2 weeks) pevonedistat in combination with the standard-of-care chemotherapy agents, docetaxel and carboplatin plus paclitaxel until they experienced symptomatic deterioration or progressive disease, or until their treatment was discontinued for another reason (Part B). Here we report the results from Part A. As the impact of CYP3A inhibition on pevonedistat systemic exposure was unknown at the time of
What is already known about this subject
• Pevonedistat is a first-in-class inhibitor of NEDD8-activating enzyme within the ubiquitin-proteosome system, which regulates cullin-RING ligases (CRL), a family of E3 ligases controlling the ubiquitination and proteasomal degradation of CRL-dependent substrates, including proteins with important roles in cell cycle progression, DNA replication, oxidative stress response, and signal transduction. These cellular processes are relevant to tumour cell growth, proliferation, and survival, thereby providing a rationale for investigating pevonedistat as an anticancer agent.
• Pevonedistat was predominantly metabolised by CYP3A4 in vitro, and was shown to be a P-gp substrate, suggesting the potential for a clinically meaningful drug-drug interaction with strong inhibitors of CYP3A or P-gp.
What this study adds
• The moderate CYP3A inhibitor fluconazole and the strong CYP3A/P-gp inhibitor itraconazole had no clinically meaningful effects on pevonedistat pharmacokinetics.
• Pevonedistat can be co-administered without dose modifications with strong CYP3A/P-gp inhibitors including azole antifungal agents, which are commonly used treatments in patients with haematological malignancies.
designing this DDI study, the effect of fluconazole, a moderate CYP3A
inhibitor, was evaluated first, before proceeding to conduct the DDI assessment with itraconazole, a strong CYP3A inhibitor, as a conservative measure in the interest of patient safety. Secondary objectives were to assess the safety and tolerability of pevonedistat in combination with fluconazole or itraconazole.
Pevonedistat was supplied as 10 mg mL −1 vials (BSP Pharmaceuticals), fluconazole as a 200 mg oral tablet (Teva) 16 and itraconazole as a 10 mg mL −1 oral solution (Janssen). 17 All doses of fluconazole and itraconazole were administered on an empty stomach with the patient fasting from food and fluids, except water and prescribed medications, with the purpose of confirming that the PK and safety were adequate, based on data from three PK-evaluable patients. The administration of the last dose of fluconazole or itraconazole was followed by at least a 2-week, and up to 8-week, drug washout period. The concomitant medications that patients were prohibited from taking during the study are listed in Supplementary Table S1 .
The study protocol and amendments were approved by the 
| Patients
To be eligible for enrolment, adult patients were required to have a histologically or cytologically confirmed metastatic or locally advanced solid tumour for which no effective standard treatment was available. They also required an Eastern Cooperative Oncology
Group performance status (ECOG PS) of 0 or 1, an absolute neutrophil count (ANC) ≥1500 mm −3 , a platelet count ≥100 000 mm 
| PK and statistical analyses
The PK-evaluable population was defined as all patients who received the protocol-specified doses of pevonedistat and fluconazole or itraconazole. The safety population comprised all patients who received at least one dose of pevonedistat.
The sample size calculation was based on the expected two-sided 90% confidence interval (CI) for the difference in the paired, logtransformed AUC (or C max ) means of pevonedistat on day 8
(pevonedistat co-administered with CYP3A inhibitor) and day 1 (pevonedistat alone). Based on the PK information obtained from previous studies, the within-subject coefficient of variation (CV) was estimated to be 0.12 for AUC and 0.17 for C max , respectively. pevonedistat cohorts, and three additional PK-evaluable patients were to be enrolled in the 15 mg m −2 safety lead-in cohort. Assuming 25%
of the enrolled cancer patients may not be PK-evaluable, approximately 52 patients in total were planned for the study. 
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY, 20 and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18.
21,22
3 | RESULTS
| Patients and treatment exposure
A total of 51 patients were enrolled in the study and received pevonedistat plus fluconazole (n = 13) or pevonedistat plus itraconazole (n = 38). Overall, 47% of the patients were male, and most were white (80% ). The most common cancer types were pancreatic (12%), breast, oesophageal, non-small cell lung and sarcoma (8% each) and ovarian (6%). All 51 patients had received at least one prior therapy, including chemotherapy (100%), surgery (90%) and radiation therapy (43%). Detailed patient baseline demographics and disease characteristics are summarized in Supplementary Table S2 .
Forty-five patients (88%) received both scheduled doses of pevonedistat. Six patients received only one of the two scheduled pevonedistat doses: one had pevonedistat held in the pevonedistat plus fluconazole group, and one had pevonedistat held and four discontinued study drug in the pevonedistat 20 mg m −2 plus itraconazole group. Fifteen patients (29%) discontinued study treatment due to symptomatic deterioration (n = 7, 14%), AEs (n = 6, 12%), withdrawal of consent (n = 1, 2%), or ineligibility to participate in Part B because of alkaline phosphatase abnormality (n = 1, 2%).
| Pharmacokinetics
Data from 12 patients who were PK-evaluable were assessed for the effects of fluconazole on the PK of pevonedistat administered at 8 mg m −2 . The mean plasma concentration-time profiles and summary statistics of PK parameters for pevonedistat in patients treated on day 1 with pevonedistat alone (reference condition) and on day 8 with pevonedistat plus fluconazole (test condition) are shown in Figure 2A and Data from 33 patients who were PK-evaluable were assessed for the effects of itraconazole on the PK of pevonedistat administered Table 2 ). On the basis of these observations, additional patients were Geometric mean (% CV).
b Mean (standard deviation).
AUC last , area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration; AUC ∞ , area under the plasma concentration-time curve from 0 to infinity, calculated using the value of the last quantifiable concentration; C max , maximum observed plasma concentration; CL, clearance; CV, coefficient of variation; PK, pharmacokinetics; t 1/2 , terminal elimination half-life.
enrolled to assess the effects of itraconazole on pevonedistat PK at higher and clinically relevant doses. While not an objective of the study, the ANOVA results for the 15 mg m −2 safety lead-in cohort showed that the mean AUC ∞ ratio was 133%; some caution should, however, be applied when interpreting these data given the small sample size of six patients for reliable estimation, as evidenced by the wide 90% Table 2 .
| Safety
All patients were included in the safety population, of which 50 patients (98%) experienced at least one AE and 28 (55%) experienced at least one drug-related AE. The most common AEs by preferred term are listed in Table 3 . Across all study groups, the most common drugrelated AEs included vomiting (n = 6, 12%), diarrhoea (n = 5, 10%), nausea (n = 4, 8%), and increased AST, fatigue, pruritus, anaemia and decreased appetite (n = 3, 6% each). Fifty-five percent (n = 28) of patients experienced AEs with a maximum intensity of only grade 1 or 2, while 43% (n = 22) of patients reported at least one grade ≥3 AE. Two patients (5%) in the pevonedistat plus itraconazole group Natural log-transformed dose-normalized PK parameters were fit using a mixed effects model with study day as a fixed effect and patient as a random effect. Geometric LS means and geometric LS mean ratio were back-transformed LS mean and treatment mean differences.
AUC last , area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration; AUC ∞ , area under the plasma concentration-time curve from 0 to infinity, calculated using the value of the last quantifiable concentration; C max , maximum observed plasma concentration; CI, confidence interval; DDI, drug-drug interaction; LS, least-squares; PK, pharmacokinetics.
had drug-related grade ≥3 AEs of diarrhoea (n = 1) and increased ALT and increased AST (n = 1). Thirteen patients (25%) had serious AEs, which were not deemed to be drug-related, and seven patients (14%) discontinued the study due to AEs. Overall, seven patients Fluconazole and itraconazole are among the choices of moderate and strong inhibitors of CYP3A, respectively, recommended in regulatory guidelines. 14, 15 Itraconazole was chosen instead of ketoconazole based on FDA communications advising against the use of ketoconazole for DDI studies due to serious side effects. 25 Because of the known overlap in CYP3A and P-gp specificity, several azole (16) 7 (18) 7 (14) Hyponatraemia 2 (15) 1 (8) 1 (17) 2 (11) 4 (11) 6 (12)
All data are shown as n (%).
antifungals effectively inhibit the human P-gp transport function; however, they do not necessarily share similar inhibition potency on the enzyme and transporter. While itraconazole is a strong dual inhibitor of CYP3A and P-gp, fluconazole is classified as a moderate CYP3A
inhibitor, but devoid of P-gp inhibitory effect. 26, 27 As the extent of DDIs between CYP3A and/or P-gp inhibitors and pevonedistat was uncertain at the time of designing this study, in the interest of patient safety we utilized a conservative approach and analysed the effects of fluconazole before proceeding to conduct the DDI assessment with itraconazole. Additionally, the pevonedistat dose was started at . The systemic exposure of pevonedistat in the presence of itraconazole was only minimally increased compared with that in the absence of itraconazole (geometric mean dose-normalized AUC ∞ ratio of 1.14, with an associated 90% CI of 1.07-1.23). The 90% CI of the AUC ∞ geometric mean ratio was contained within the 80-125% statistical equivalence range. 15 In addition, the 14% increase in the pevonedistat geometric mean dose-normalized AUC ∞ was not considered clinically meaningful when viewed in the context of overall pevonedistat PK variability (CV of 15-34% in The hydroxylation/oxidation pathway leading to the major metabolites accounts for approximately 70% of the total dose. In vitro enzymology studies of the primary human biotransformation pathways of pevonedistat, including reaction phenotyping, at clinically relevant concentrations are ongoing to identify hepatic and extrahepatic enzymes involved in pevonedistat metabolism.
The toxicity profile of pevonedistat in combination with fluconazole or itraconazole was consistent with that reported in previous single-agent pevonedistat studies. 6, 10, 11, 13 More than 50% of patients experienced AEs with a maximum intensity of grade 1 or 2, and the only drug-related grade 3 AEs, observed in two patients who received pevonedistat plus itraconazole, were diarrhoea (n = 1) and increased ALT and increased AST (n = 1). Although the patient numbers were small in each subgroup, there were no clinically relevant differences in the frequency or severity of AEs between the fluconazole and itraconazole groups or among the pevonedistat dose subgroups in the pevonedistat plus itraconazole group.
In conclusion, fluconazole, a moderate CYP3A inhibitor, and itraconazole, a strong CYP3A/P-gp inhibitor, had no clinically meaningful effects on pevonedistat PK. The clinical PK profile of pevonedistat is comparable in patients with haematological or solid tumour malignancies 6, 10, 11, 13, 30 and therefore, the study results indicate that the use of moderate/strong CYP3A inhibitors and P-gp inhibitors is permitted in patients receiving pevonedistat, regardless of the cancer type. Of particular relevance, no dose adjustment of pevonedistat is needed when co-administered with CYP3A-inhibitory azole antifungal agents (e.g., itraconazole, posaconazole), which are commonly used medications for systemic fungal infections in patients with haematologic malignancies. 
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